Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Jefferson U, Pyrosequencing in IBD Research Collaboration

NEW YORK, March 31 - Thomas Jefferson University has purchased a PSQ HS 96A genotyping system from Pyrosequencing as part of a collaborative agreement to analyze genes and develop applications for inflammatory bowel disease (IBD), the company said today.

 

The university will use the genotyping system to study genetic variations in genes related to IBD. Ultimately, it plans to develop a gene-based diagnostic tool "that we expect to be much simpler and faster, while as effective as current methods," said Paolo Fortina, professor of Medicine at Jefferson Medical College of Thomas Jefferson University.

 

Pyrosequencing will commercialize any molecular diagnostic products relating to the IBD research in collaboration with a third party, said Jerry Williamson, president of Pyrosequencing.

 

The agreement builds on an existing collaboration between Pyrosequencing and Fortina on gene-based diagnostic tests for hearing loss. Fortina used Pyrosequencing's technology to study variations in the connexin 26 gene implicated in a common type of inherited hearing loss.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.